What type of study is this?

September 5, 2025Open Access

Supplementary Figure 3 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited

View Full Paper

Ask AI

Bookmark

Bicistronic CAR T-cells control myeloma cells even with limited BCMA expression, demonstrating effectiveness against this cancer.
Proliferation of CAR T-cells was notably observed when co-cultured with K562 cell lines expressing CD229 antigen.
The effectiveness of CAR T-cells against myeloma was gauged over a 72-hour co-culture period with K562 cell lines.
These findings suggest that targeting both BCMA and CD229 may enhance treatment options for myeloma patients.

CAR T-cell proliferation shows effectiveness against myeloma in K562 cell lines despite limited BCMA expression.

CAR T-cell proliferation when co-cultured for 72 hours with K562 cell lines with different expression of CD229 antigen

No takes yet. Share an insight, caveat, or question.

Rodríguez‐Lobato et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

CAR T-cell proliferation shows effectiveness against myeloma in K562 cell lines despite limited BCMA expression.

CAR T-cell proliferation when co-cultured for 72 hours with K562 cell lines with different expression of CD229 antigen